A comprehensive narrative review evaluating the cellular pathology and clinical risk assessment of dilated cardiomyopathy indicates that relying solely on left ventricular ejection fraction fails to detect a substantial proportion of patients vulnerable to malignant ventricular arrhythmias and sudden cardiac death. Writing in Frontiers in Cardiovascular Medicine, investigators Linli Shi and Xin Li from the Department of Emergency Medicine at Guangdong Provincial People’s Hospital synthesized clinical and experimental investigations published between January 2000 and May 2026. Dilated cardiomyopathy, a myocardial disorder characterized by ventricular enlargement and systolic dysfunction that affects an estimated one in 250 to 500 individuals globally, carries an unpredictable risk of fatal arrhythmias. The authors demonstrate that the conventional clinical threshold of an ejection fraction at or below 35 percent provides poor discriminative accuracy, yielding an area under the receiver operating characteristic curve of only 0.50 to 0.56. Because roughly half of all sudden cardiac deaths occur in individuals with preserved or only moderately reduced ejection fractions, precision management requires replacing the single functional metric with a multidimensional framework that integrates cellular calcium regulation, high-risk genetic variants, and quantitative tissue characterization by cardiac magnetic resonance.
At the subcellular level, disrupted calcium handling within cardiomyocytes serves as an initial functional trigger that provokes electrical instability before or alongside overt mechanical failure. Physiological excitation-contraction coupling depends upon the tightly orchestrated cycling of intracellular calcium ions mediated by sarcolemma L-type calcium channels, ryanodine receptor 2 release channels on the sarcoplasmic reticulum, and the sarcoplasmic reticulum calcium ATPase pump known as SERCA2a. In dilated cardiomyopathy, pathological remodeling compromises these molecular checkpoints. Calcium and calmodulin-dependent protein kinase II delta becomes hyperactivated and phosphorylates ryanodine receptor 2 at serine 2814, lowering its activation threshold and causing pathological calcium leakage into the cytosol during diastole. This diastolic leak can generate early and delayed afterdepolarizations, triggering spontaneous action potentials. Concurrently, diminished SERCA2a expression and altered phospholamban regulation impair cytosolic calcium clearance during diastole, compounding intracellular calcium overload. Distinct from ischemic cardiomyopathy where L-type calcium channels are primarily overactivated through protein kinase A pathways, dilated cardiomyopathy channels are driven predominantly by calcium and calmodulin-dependent protein kinase II, producing abnormal inward currents during the action potential plateau that initiate triggered arrhythmic events.
The review emphasizes that significant mechanistic ambiguities and translational gaps persist regarding intracellular calcium dysregulation across different clinical contexts and experimental models. Studies examining tissue samples from patients with dilated cardiomyopathy report discordant findings regarding the absolute magnitude of ryanodine receptor serine 2814 phosphorylation, the relative contributions of distinct calcium and calmodulin-dependent protein kinase isoforms, and whether myocardial L-type calcium channel density is increased, decreased, or unchanged. Furthermore, substantial electrophysiological differences exist between small-animal experimental models and human myocardium, complicating direct clinical translation. Therapeutic trials directly targeting SERCA2a restoration or kinase inhibition have yielded inconsistent clinical benefits and have not reliably suppressed ventricular arrhythmias in clinical populations. The authors emphasize that calcium-mediated triggered activity cannot independently sustain life-threatening re-entrant arrhythmias; rather, it provides the initiating electrical trigger, requiring structural tissue abnormalities such as fibrosis and slowed myocardial conduction to establish persistent, self-sustaining ventricular tachycardia or fibrillation circuits.
Underlying this cellular remodeling is profound genetic heterogeneity, encompassing more than one hundred recognized causative genes encoding sarcomeric, structural, nuclear envelope, and ion channel proteins. While truncating variants in the titin gene represent the single most common inherited cause of dilated cardiomyopathy, accounting for approximately 25 percent of familial presentations, their arrhythmic risk tracks closely with the degree of pump failure. A cohort investigation tracking 537 titin variant carriers over a median of 49 months documented that malignant ventricular arrhythmias occurred predominantly among patients suffering from severe systolic impairment, with each 10 percent decline in ejection fraction elevating composite endpoint risk by 1.63-fold. By contrast, specific high-risk genotypes decouple arrhythmic vulnerability from mechanical pumping function entirely. Pathogenic variants occurring in genes encoding lamin A/C, filamin C, RNA binding motif protein 20, and desmosomal junctional components generate severe ventricular arrhythmia risks even in individuals presenting with preserved or only mildly reduced left ventricular ejection fractions.
Among high-risk arrhythmogenic genotypes, lamin A/C mutations confer an exceptionally dangerous phenotype characterized by progressive atrioventricular conduction blocks, atrial fibrillation, and sudden death. A validated prediction score derived from 839 adult carriers identified male sex, non-missense variants, atrioventricular conduction delay, non-sustained ventricular tachycardia, and ejection fraction as independent predictors of life-threatening events, establishing a model-derived 5-year risk threshold of 7 percent for sensitive prediction and 10 percent for clinical implantable cardioverter-defibrillator consideration. Truncating variants in filamin C similarly carry a high 5-year incidence of sudden cardiac death or malignant arrhythmias of 27 percent, as documented in an initial cohort of 85 carriers followed for 61 months and subsequently validated in an international cohort of 308 patients. Similarly, pathogenic missense variants in RNA binding motif protein 20 produce penetrant arrhythmogenic disease: a multicenter study of 62 carriers revealed a 31 percent incidence of malignant ventricular arrhythmias occurring at a mean age of 45 years, alongside higher male vulnerability, while a literature review of 678 patients across 34 studies demonstrated a 24 percent pooled arrhythmia incidence and a 12 percent requirement for mechanical circulatory support or cardiac transplantation.
Variants in desmosomal genes, including desmoplakin, plakophilin-2, desmoglein-2, and desmocollin-2, generate malignant arrhythmia rates comparable to lamin A/C and filamin C, frequently displaying left ventricular-dominant fibrofatty replacement that overlaps phenotypically with arrhythmogenic right ventricular cardiomyopathy. A multicenter cohort of 742 patients highlighted that the coexistence of non-sustained ventricular tachycardia and syncope raised the diagnostic yield for high-risk genotypes from 8 percent to 30 percent. In contrast, mutations in SCN5A, which encodes the cardiac voltage-gated sodium channel Nav1.5, present a distinct therapeutic opportunity. A systematic analysis of 173 affected individuals from 29 families harboring transmembrane voltage-sensing domain variants identified frequent polymorphic premature ventricular contractions in 72 percent and ventricular arrhythmias in 33 percent of cases. Uniquely, SCN5A-associated myocardial dysfunction responds robustly to sodium channel blocking agents, leading to functional cardiac recovery; however, the authors caution that these observations stem from small retrospective family cohorts requiring prospective multicenter validation before universal therapeutic adoption.
Myocardial fibrosis constitutes the physical substrate that anchors sustained re-entrant ventricular tachyarrhythmias by disrupting normal tissue architecture, creating conduction slowing, and promoting electrical anisotropy. Late gadolinium enhancement imaging via cardiac magnetic resonance allows clinicians to detect focal replacement scarring that affects roughly one-third of dilated cardiomyopathy patients, conferring a fivefold to ninefold increase in sudden death risk. A multicenter investigation of 1,105 patients demonstrated that late gadolinium enhancement involving at least 7.2 percent of total left ventricular mass strongly predicted sudden cardiac death, carrying an annual event rate of 4.7 percent. A complementary study examining 1,272 individuals with severe systolic dysfunction, defined by an ejection fraction at or below 35 percent, established that late gadolinium enhancement of at least 7.5 percent increased sudden death hazard threefold compared to lower scar burdens. Long-term follow-up of 1,668 patients over a median of 9 years verified that scar extent, septal location, and multi-regional enhancement predicted all-cause mortality, yielding a net reclassification improvement of 64.3 percent over traditional ejection fraction metrics.
Different arrhythmogenic genetic profiles produce distinctive scar morphology on contrast imaging, providing valuable diagnostic synergy. Patients harboring lamin A/C variants often exhibit an apical transmural scar pattern resembling myocardial infarction, which carries a 2.39-fold increased hazard for major ventricular arrhythmias, whereas the complete absence of late gadolinium enhancement over 10 years of observation in one study was associated with zero ventricular events. Conversely, patients carrying filamin C truncating variants typically present with a distinctive mid-wall subepicardial ring-like scar pattern that independently predicts sustained arrhythmia hazards. However, the review notes significant technical limitations inherent to contrast imaging. Late gadolinium enhancement primarily captures focal replacement scarring and fails to reliably quantify diffuse interstitial collagen deposition. Quantification remains sensitive to variations in contrast dosing, scanning protocols, thresholding algorithms, and post-processing software across imaging centers.
To translate these biological and imaging discoveries into practical bedside care, the authors evaluate a stepwise diagnostic algorithm originating from the Fuwai Hospital clinical workflow. In patients eligible for contrast magnetic resonance imaging, the detection of late gadolinium enhancement equaling or exceeding 7.2 percent of ventricular mass directly categorizes the individual as high risk. For patients displaying scar burden below this threshold, secondary stratification evaluates extracellular volume fraction and ventricular function: an extracellular volume of at least 31.8 percent paired with an ejection fraction of 35 percent or less denotes intermediate risk, whereas an extracellular volume below 31.8 percent alongside an ejection fraction exceeding 35 percent identifies a low-risk subgroup with an annual sudden cardiac death incidence of only 0.2 percent. When contrast administration is contraindicated, native T1 z-scores, non-sustained ventricular tachycardia episodes, and clinical modifiers provide alternative stratification. When imaging modalities are inaccessible, clinicians can employ a logistic regression prediction tool derived from 610 patients that incorporates patient age, ejection fraction, blood glucose, serum potassium, and estimated glomerular filtration rate, which achieved an internal validation area under the curve of 0.800 and an external validation score of 0.760.
When diagnostic findings conflict across clinical parameters, the authors propose clear hierarchical rules: confirmed high-risk genotypes or late gadolinium enhancement meeting or exceeding 7.2 percent dominate the clinical assessment and designate the patient as high risk, regardless of whether ventricular ejection fraction remains preserved. Clinical modifiers including syncope, documented non-sustained ventricular tachycardia, conduction disorders, or family history of sudden death elevate the assigned risk category. Nevertheless, the authors emphasize important systemic limitations in current evidence. Most available studies remain retrospective and observational, subject to referral and publication biases and center-specific variations in image quantification. Furthermore, clinical trials directly demonstrating that biomarker-guided implantable cardioverter-defibrillator placement improves survival over standard care remain ongoing, including the CMR-ICD and CMR GUIDE DCM randomized trials. Expanding device eligibility also introduces clinical harms, including inappropriate shocks, procedural infections, psychological distress, and health care costs, while genetic testing introduces concerns surrounding insurance coverage and anxiety. Until prospective randomized trial data mature, this multidimensional framework functions as a structured evidence synthesis rather than a prescriptive guideline, offering clinicians a rigorous path toward precision risk assessment in dilated cardiomyopathy.
Subject of Research: Multidimensional risk stratification and molecular mechanisms of ventricular arrhythmias in dilated cardiomyopathy
Article Title: Molecular mechanisms and risk stratification of malignant ventricular arrhythmias in dilated cardiomyopathy: a comprehensive review
Article References: Shi, L., & Li, X. (2026). Molecular mechanisms and risk stratification of malignant ventricular arrhythmias in dilated cardiomyopathy: a comprehensive review. Frontiers in Cardiovascular Medicine, 13, 1942101. https://doi.org/10.3389/fcvm.2026.1942101
Image Credits: AI Generated
DOI: 10.3389/fcvm.2026.1942101
Keywords: dilated cardiomyopathy, ventricular arrhythmias, sudden cardiac death, cardiac magnetic resonance, late gadolinium enhancement, LMNA gene, FLNC truncating variants, RBM20 mutation, titin gene variants, desmosomal variants, SCN5A sodium channel, calcium handling remodeling, ryanodine receptor 2, SERCA2a calcium pump, extracellular volume fraction, implantable cardioverter defibrillator, risk stratification
News Source: Ophelia Keating. (November 13, 2026). Multidimensional Assessment Improves Arrhythmia Risk Prediction in Dilated Cardiomyopathy. Scienmag.



